Dr. Paul Aiyetan has almost two decades of experience and expertise spanning medicine, oncology, pathology, computational systems biology, translational bioinformatics, and clinical diagnostics development. He has previously led diverse high-performing teams and collaboration efforts in academia, government, and industry. 

He is currently the Founder and CEO of NEOPATHOLOGY Corp., a biotechnology research and clinical diagnostic development company in Frederick, Maryland. NEOPATHOLOGY is developing a new generation of highly accurate and rapidly reported precision tissue diagnostics and assays that make more accurate diagnosis and help clinicians stratify specific disease patients for better treatment and clinical outcomes. Dr. Aiyetan also leads NEOPATHOLOGY’s research, development, and translational efforts. 

Dr. Aiyetan was formerly at the National Cancer Institute, the Frederick National Laboratory for Cancer Research, InterVenn Biosciences, the Medical Diagnostics Laboratory Institute for Biomarker Research, and the Johns Hopkins University School of Medicine. 

Dr. Aiyetan has published in many highly ranked research journals, including Nature Biotechnology and Cell. Dr. Aiyetan obtained his medical degree from the College of Medicine, University of Ibadan, an M.S. degree from Johns Hopkins University, and a Ph.D. from George Mason University. Dr. Aiyetan was a postdoctoral fellow in pathology at the Johns Hopkins University School of Medicine. While at the Center for Biomarker Discovery and Translation, he was an investigator on the National Cancer Institute funded Clinical Proteomics Tumor Analysis Consortium (CPTAC) and the National Heart, Lung and Blood Institute funded Programs of Excellence in Glycosciences (PEG). 

Dr.  Aiyetan participated in an NSF-sponsored I-Corps Mid-Atlantic Region cohort from May to August 2023.